Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectivesLaurent Abel, William R. Bishai, Jacques Fellay et al.|The Lancet Infectious Diseases|2017Cited by 178
140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLCEnriqueta Felip, Apar Kishor Ganti, Daniel Johnson et al.|Annals of Oncology|2021Cited by 1